Immunotherapy for Kidney Cancer
Joseph I. Clark, MDImmunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials.Although surgical resection (removal) of the kidney is often used in patients with l...
Source: Kidney Cancer Association - July 19, 2014 Category: Urology & Nephrology Source Type: news

Mayo Clinic researchers reveal treasure trove of genes key to kidney cancer
(Mayo Clinic) A genomic analysis of clear cell renal cell carcinoma, the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2014 Category: Global & Universal Source Type: news

Mayo Clinic Researchers Reveal Treasure Trove of Genes Key to Kidney Cancer
JACKSONVILLE, Fla. — A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. Eight of these genes had not been previously linked to [...] (Source: Mayo Clinic Jacksonville News)
Source: Mayo Clinic Jacksonville News - July 1, 2014 Category: Hospital Management Source Type: news

In conversation with “e-Patient Dave”
“e-Patient Dave” is a leading advocate for engaging patients in their care and allowing patients to access their medical records. He also coauthored Let Patients Help: A Patient Engagement Handbook. He was diagnosed in 2007 with metastatic renal cell cancer.  In this conversation, Dave discusses his views on the relationship with the patient in patient care and patient safety.  (http://webmm.ahrq.gov/perspective.aspx?perspectiveID=159)  (bbj)   (Source: Midcontinental Region News)
Source: Midcontinental Region News - June 30, 2014 Category: Databases & Libraries Authors: liaison Tags: General Interest Health Sciences Libraries Public Libraries Source Type: news

Podcast: About Kidney Cancer
Your browser does not support native audio, but you can download this MP3 to listen on your device. Renal cell carcinoma (RCC) is the most common type of kidney cancer, with more than 200,000 new cases of RCC diagnosed worldwide each year, and 25-30% of kidney cancer patients diagnosed with metastatic disease. With advancements in medical science, patients with advanced RCC can now have better chances of surviving cancer as Professor Dr. Marniza Saad informs us  06/27/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2014 Category: Cancer & Oncology Source Type: news

Podcast: About Kidney Cancer
Your browser does not support native audio, but you can download this MP3 to listen on your device. Renal cell carcinoma (RCC) is the most common type of kidney cancer, with more than 200,000 new cases of RCC diagnosed worldwide each year, and 25-30% of kidney cancer patients diagnosed with metastatic disease. With advancements in medical science, patients with advanced RCC can now have better chances of surviving cancer as Professor Dr. Marniza Saad informs us  06/27/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2014 Category: Urology & Nephrology Source Type: news

Podcast: About Kidney Cancer
Your browser does not support native audio, but you candownload this MP3 to listen on your device.Renal cell carcinoma (RCC) is the most common type of kidney cancer, with more than 200,000 new cases of RCC diagnosed worldwide each year, and 25-30% of kidney cancer patients diagnosed with metastatic disease. With advancements in medical science, patients with advanced RCC can now have better chances of surviving cancer as Professor Dr. Marniza Saad informs us 06/27/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2014 Category: Urology & Nephrology Source Type: news

Gene in brain linked to kidney cancer, researchers say
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers are reporting. The research reveals that the gene NPTX2, plays an essential role in this cancer type, which is resistant to common chemotherapy and has a five-year overall survival rate of less than 10 percent in patients with metastatic disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 24, 2014 Category: Science Source Type: news

Mayo Clinic researchers say gene in brain linked to kidney cancer
(Mayo Clinic) A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 24, 2014 Category: Global & Universal Source Type: news

Mayo Clinic Researchers Say Gene in Brain Linked to Kidney Cancer
JACKSONVILLE, Fla. — A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. https://www.youtube.com/watch?v=jJ_8vv97wIA Their study, published in Cancer Research, reveals that the gene NPTX2, plays an essential role in this cancer [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - June 24, 2014 Category: Research Source Type: news

“Mayo Clinic Researchers Say Gene in Brain Linked to Kidney Cancer,” Mayo Clinic Cancer Center
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting. In this video, John A. Copland, PhD, molecular biologist and this study's senior investigator, discusses the findings of a recent study, which was published in Cancer Research. Mayo Clinic Cancer Center is one of the 25 NCCN Member Institutions. ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - June 24, 2014 Category: Cancer & Oncology Source Type: news

Radiation Therapy: Curative Option for RCC?Radiation Therapy: Curative Option for RCC?
Dr. Gert De Meerleer discusses the use of stereotactic body radiation therapy (SBRT) to control and potentially cure limited metastatic disease in renal cell carcinoma. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2014 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news

An Unused Curative Option in RCC?An Unused Curative Option in RCC?
Dr. Gert De Meerleer discusses the use of stereotactic body radiation therapy (SBRT) to control and potentially cure limited metastatic disease in renal cell carcinoma. Medscape Oncology (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - June 23, 2014 Category: Urology & Nephrology Tags: Hematology-Oncology Expert Interview Source Type: news

MET is a potential target across all papillary renal cell carcinomas
Recent report of MET inhibition strengthened the role of c–Met inhibition across pRCC.06/17/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 17, 2014 Category: Cancer & Oncology Source Type: news

Six Organizations Receive Grants from NCCN and Pfizer for Health Care Quality Improvement Programs in Rare Cancers
The NCCN Oncology Research Program (ORP) and Pfizer Independent Grants for Learning & Change have awarded six independent grants to implement quality improvement and health care professional education in renal cell carcinoma and hematologic malignancies. FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP), in collaboration with Pfizer Independent Grants for Learning & Change (IGLC), recently awarded six independent grants to hea... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - June 11, 2014 Category: Cancer & Oncology Source Type: news

ASCO 2014 Renal Cell Carcinoma Abstracts
Abstracts mentioning renal cell carcinoma (kidney cancer) from the 2014 ASCO Annual Meeting in Chicago.05/31/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 31, 2014 Category: Cancer & Oncology Source Type: news

Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC - See more at: http://www.onclive.com/conference-coverage/aua-2014/Cell-Cycle-Gene-Test-Shows-Early-Promise-in-Clear-Cell-RCC#sthash.DhoRovxs
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology...05/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 21, 2014 Category: Cancer & Oncology Source Type: news

Treatment Choices in mRCCTreatment Choices in mRCC
How to make the choice of treatment options for patients with metastatic renal cell carcinoma? Dr. Viktor Grünwald, author of a recent review, sorts out the evidence. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Expert Interview Source Type: news

Tailoring Therapy in Renal Cell CarcinomaTailoring Therapy in Renal Cell Carcinoma
How to make the choice of treatment options for patients with metastatic renal cell carcinoma? Dr. Viktor Grünwald, author of a recent review, sorts out the evidence. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Expert Interview Source Type: news

IL-2 for Kidney Cancer Offers CureIL-2 for Kidney Cancer Offers Cure
High-dose interleukin-2 is still a viable treatment option for metastatic renal cell carcinoma, because it is the only truly curative option for advanced disease. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Surgical strategies available for renal cell carcinoma
Prof Wood talks to ecancertv at the EIKCS conference about the different surgical strategies available for approaching renal cell carcinoma with inferior vena cava invasion and their outcomes post-surgery.05/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 7, 2014 Category: Cancer & Oncology Source Type: news

Study Confirms Clinical Benefit for Interleukin-2
Patients with metastatic renal cell carcinoma face a poor prognosis; currently, 30% of patients already have metastatic disease at the time of diagnosis, according to national data.05/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 7, 2014 Category: Cancer & Oncology Source Type: news

Bristol-Myers Squibb Continues to Lead the Advancement of Immuno-Oncology
Results for nivolumab and Yervoy® (ipilimumab) as a combination regimen in three tumor types to be presented, including melanoma and the first findings in non-small cell lung cancer and renal cell carcinoma.05/06/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 6, 2014 Category: Cancer & Oncology Source Type: news

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma
Resistance to these agents develops frequently, and their use is often limited by intolerance.05/01/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 1, 2014 Category: Cancer & Oncology Source Type: news

Papillary Renal Cell Carcinoma Clinical Trials Review 2014
Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario.05/01/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 1, 2014 Category: Cancer & Oncology Source Type: news

FREE Book: Renal Cell Carcinoma
04/18/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 18, 2014 Category: Cancer & Oncology Source Type: news

Kidney cancer survival improves
The report examines trends in survival of kidney cancer in England over 20 years (1990 to 2010) and found that people diagnosed with the main type of kidney cancer, renal cell carcinoma, have seen an overall improvement in survival. However, for around 10% of patients diagnosed with rarer types of kidney cancer such as transitional cell carcinoma (TCC), there has been no significant change. This could be because TCC is less likely to be detected early via medical imaging, but also because of less advances in developing successful treatments. (Source: NHS Networks)
Source: NHS Networks - April 17, 2014 Category: UK Health Authors: Maria Axford Source Type: news

OncoBriefs: Notable Studies from AACR (CME/CE)
SAN DIEGO (MedPage Today) -- Irregular menstrual cycles predicted an increased risk of ovarian cancer and dying of the disease, according to a study reported at the American Association for Cancer Research. Other meeting highlights included treatment advances in renal cell carcinoma, bladder cancer, and melanoma. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 14, 2014 Category: Hematology Source Type: news

OncoBriefs: Notable Studies from AACR
SAN DIEGO (MedPage Today) -- Irregular menstrual cycles predicted an increased risk of ovarian cancer and dying of the disease, according to a study reported at the American Association for Cancer Research. Other meeting highlights included treatment advances in renal cell carcinoma, bladder cancer, and melanoma. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 13, 2014 Category: Hematology Source Type: news

Case report: long-lasting response in a patient with metastatic renal cell cancer
Adoptive immunotherapy can be a therapeutic option...04/07/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 7, 2014 Category: Cancer & Oncology Source Type: news

Electroporation of Dendritic Cells with Autologous Total RNA from Tumor Material
Dendritic cells (DC) are unique antigen-presenting cells that initiate and orchestrate adaptive immunity. Theoretically, cancer cells that express tumor-specific antigens can be destroyed by cytotoxic T cells. However, inherent antitumor responses are often not efficient, since tumor cells can mask their antigens and do not activate DC, an event required for the development of tumor antigen-specific cytotoxic T cell responses. Over a decade ago, the ex vivo preparation of autologous tumor antigen-loaded monocyte-derived DC vacciness as a novel potent anticancer strategy was launched. Phase I and II trials have been perform...
Source: Springer protocols feed by Cancer Research - April 7, 2014 Category: Cancer & Oncology Source Type: news

Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma
Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12 patients with newly diagnosed kidney cancer, treated with the cancer vaccine INTUVAX®. No vaccine-related serious adverse events were noted and the report presents a hitherto achieved median survival for patients with poor prognosis that clearly exceeds the expected median survival for patients treated with established drugs.04/01/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 1, 2014 Category: Cancer & Oncology Source Type: news

Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncologyi. (Source: GSK news)
Source: GSK news - April 1, 2014 Category: Pharmaceuticals Source Type: news

Hyponatremia Associated with Poorer Overall Survival
In metastatic renal cell cancer (mRCC) patients treated with targeted therapy, baseline hyponatremia is associated with poorer overall survival (OS), time to treatment failure (TTF), and disease control rate (DCR), according to a study published in European Urology.03/29/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 29, 2014 Category: Cancer & Oncology Source Type: news

Court bans export of generic kidney, liver cancer medication
Sorafenat is the generic alternative to Bayer's Nexavar, and is used to treat a type of kidney cancer called advanced renal cell carcinoma as well as liver cancer.03/28/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 28, 2014 Category: Cancer & Oncology Source Type: news

Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma
Raman molecular imaging was evaluated as a tool for differentiating between kidney tumors which are sometimes confused using conventional histopathological methods.03/18/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 18, 2014 Category: Cancer & Oncology Source Type: news

Tyrosine kinase inhibitor sorafenib decreases (111)In-girentuximab uptake in patients with clear cell renal cell carcinoma
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC).03/14/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 14, 2014 Category: Cancer & Oncology Source Type: news

Differentiation of Oncocytoma From Chromophobe RCCDifferentiation of Oncocytoma From Chromophobe RCC
Newly described biomarkers may increase the ability to differentiate benign renal oncocytoma from other renal cell carcinomas with a greater chance of metastasis. Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Axitinib – Treatment for Advanced Renal Cell Carcinoma
Inlyta (axitinib) was developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 5, 2014 Category: Pharmaceuticals Source Type: news

Neurologic status at surgery affects metastatic spinal renal cell carcinoma survival
Neurological status at surgery, the grade of the original nephrectomy specimen and activity of the systemic disease were factors found to influence a patient’s survival after spine surgery for metastatic spinal renal cell carcinoma...02/28/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 28, 2014 Category: Cancer & Oncology Source Type: news

Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy
The survival and prognosis of mRCC patients may thus be significantly improved with the suitable use of newer targeted agents.02/26/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 26, 2014 Category: Cancer & Oncology Source Type: news

Cancer Genetics (CGIX) to Present Positive Data from UroGenRA-Kidney Test
Cancer Genetics, Inc. (Nasdaq: CGIX) announced that new data that further validates its UroGenRA-Kidney diagnostic test for renal cell cancer...02/25/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 25, 2014 Category: Cancer & Oncology Source Type: news

Perioperative blood transfusion worsens kidney cancer patients’ survival
Patients who receive blood transfusions around the time of their surgery for nonmetastatic renal cell carcinoma have a worse chance of survival than those who do not, results of a large US study suggest. (Source: MedWire News - Urology)
Source: MedWire News - Urology - February 24, 2014 Category: Urology & Nephrology Source Type: news

Perioperative blood transfusion worsens kidney cancer patients’ survival
Patients who receive blood transfusions around the time of their surgery for nonmetastatic renal cell carcinoma have a worse chance of survival than those who do not, results of a large US study suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 24, 2014 Category: Cancer & Oncology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.02/23/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 23, 2014 Category: Cancer & Oncology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. (Source: MedWire News - Urology)
Source: MedWire News - Urology - February 21, 2014 Category: Urology & Nephrology Source Type: news

Altering sunitinib dosing schedule improves tolerability
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 21, 2014 Category: Cancer & Oncology Source Type: news

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies
To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US.02/20/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2014 Category: Cancer & Oncology Source Type: news